← Back to Search

Behavioural Intervention

Behavioral Nudges for Flu Shot Uptake (BE IMMUNE Rep Trial)

N/A

Waitlist Available

Led By Shivan Mehta, MD, MBA, MSHP

Research Sponsored by University of Pennsylvania

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 months

Awards & highlights

No Placebo-Only Group

Summary

This trial will test if personalized reminders to both doctors and patients can increase flu vaccination rates in older adults. The study will last for 6 months and will involve sending text message reminders to patients before their

Who is the study for?

This trial is for older adults who are due to receive their flu vaccine, following CDC guidelines. It's designed to see if reminders and prompts (nudges) can help increase vaccination rates. People in the study will get text messages or have orders set up in their health records to remind them.

What is being tested?

The study tests whether different types of 'nudges' like pre-visit texts and monthly feedback to clinicians can boost flu shot numbers. Some high-risk patients will get extra nudges. Clinics are randomly chosen for standard reminders or these intensified efforts.

What are the potential side effects?

Since this trial focuses on behavioral nudges rather than medical treatments, there aren't direct side effects from interventions like you'd expect with drugs or surgeries. However, participants may experience inconvenience or annoyance from frequent messaging.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Proportion of patients who receive the flu vaccine at the visit

Secondary study objectives

Proportion of patients who receive the flu vaccine within 3 months after the visit

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Intervention ArmExperimental Treatment3 Interventions

Clinics randomized to the intervention arm will receive the toolkit of clinician and patient facing nudges. Patient nudges will be pre-visit text message reminders (standard messaging content). Clinician nudges will be monthly peer comparison feedback and default pended orders.

Group II: High Risk Intensification ArmExperimental Treatment4 Interventions

Patients in the intervention clinics identified as high risk for noncompletion of the flu vaccine will be randomized 1:1 to receive the high risk intensification arm or remain in the standard intervention arm. Patients in the high risk intensification arm will receive an additional bidirectional texting component.

Group III: ControlActive Control1 Intervention

Clinics randomized to the control arm will receive standard of care.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Monthly peer comparison feedback

2023

N/A

~80070

High risk bidirectional pre-visit text messaging

2023